Trial Profile
A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2021
Price :
$35
*
At a glance
- Drugs Gimsilumab (Primary)
- Indications Acute lung injury; COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Registrational; Therapeutic Use
- Acronyms BREATHE
- Sponsors Kinevant Sciences GmbH
- 15 Nov 2021 Results from subgroup analysis assessing a signal of benefit in patients invasively ventilated at baseline at the American Heart Association Scientific Sessions 2021
- 02 Apr 2021 Status changed from active, no longer recruiting to completed.
- 28 Oct 2020 Planned primary completion date changed from 1 Oct 2020 to 1 Nov 2020.